EUVIMEDEUVIMED entdecken
Crossref

Study on the mechanism of costunolide inhibiting triple-negative breast cancer by EGFR ubiquitination and degradation to suppress the ERK/AKT signaling pathway

Ying Li, Junjie Mu, Qiuxiong Chen, Qian Ming, Chaohong Zhu, Yujie Xiao, Baoli Qiu, Xue Zhang, Baoshun Zhang, Xian Yang

Journal of Molecular Histology · 2025

DOI: 10.1007/s10735-025-10604-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Histology, 2025. Verfasst von Ying Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Research Center for Biotechnology of Active Substances, Ministry of Education, Chongqing Normal University, Chongqing, 401331, People's R…. Hauptthemen laut MEDLINE: ErbB Receptors, Proto-Oncogene Proteins c-akt, Triple Negative Breast Neoplasms, Sesquiterpenes. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Chongqing Municipal Health Commission, the Chongqing Municipal Education Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Costunolide (COS) is a bioactive sesquiterpene lactone compound extracted from Aucklandia lappa, known for its anticancer, anti-inflammatory, and antioxidant properties, aligning with the traditional Chinese medicine theory of "clearing heat and dispersing nodules" in the treatment of breast ailments. Network pharmacology identified EGFR as the core target of COS, with enrichment analysis revealing the EGFR/ERK/AKT axis as a key pathway. Molecular docking demonstrated strong binding affinity of COS to the EGFR kinase domain, relying on hydrogen bonds and hydrophobic interactions. In vitro experiments showed that COS inhibited TNBC cell proliferation and induced apoptosis. Mechanistically, COS increased EGFR ubiquitination, leading to a decrease in EGFR protein levels, thereby inhibiting EGFR phosphorylation and the activation of downstream ERK and Akt signaling pathways. EGF could partially reverse the growth inhibitory effects of COS, confirming the critical role of EGFR. This study elucidates that COS exerts its anti-TNBC effects by inducing EGFR ubiquitination and degradation, thereby inhibiting the ERK/AKT signaling pathway. This finding integrates traditional Chinese medicine theory with modern molecular oncology mechanisms, providing a reference for the development of plant-derived multi-target anticancer drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsProto-Oncogene Proteins c-aktTriple Negative Breast NeoplasmsSesquiterpenesUbiquitinationSignal TransductionMAP Kinase Signaling SystemProteolysisHumansCell Line, TumorCell ProliferationMolecular Docking SimulationApoptosisFemaleLactones

Stichwörter der Autor:innen

ApoptosisCostubolideEGFRMolecular dockingNetwork pharmacologyTriple-negative breast cancer

Substanzen

ErbB ReceptorsProto-Oncogene Proteins c-aktSesquiterpenescostunolideLactonesEGFR protein, human

Autor:innen und Institutionen

  • Engineering Research Center for Biotechnology of Active Substances, Ministry of Education, Chongqing Normal University, Chongqing, 401331, People's Republic of China.
  • Chongqing Medical and Pharmaceutical College, Chongqing, 401331, People's Republic of China.
  • School of Chinese Materia Medica, Southwest University, Chongqing, 401331, People's Republic of China.
  • Engineering Research Center for Biotechnology of Active Substances, Ministry of Education, Chongqing Normal University, Chongqing, 401331, People's Republic of China. XianYang@cqnu.edu.cn.

Förderung

  • Chongqing Municipal Health Commission
  • the Chongqing Municipal Education Commission

Zitieren

APA

Li, Y., Mu, J., Chen, Q., Ming, Q., Zhu, C., Xiao, Y., Qiu, B., Zhang, X., Zhang, B., & Yang, X. (2025). Study on the mechanism of costunolide inhibiting triple-negative breast cancer by EGFR ubiquitination and degradation to suppress the ERK/AKT signaling pathway. Journal of Molecular Histology. https://doi.org/10.1007/s10735-025-10604-2

Vancouver

Li Y, Mu J, Chen Q, Ming Q, Zhu C, Xiao Y, et al. Study on the mechanism of costunolide inhibiting triple-negative breast cancer by EGFR ubiquitination and degradation to suppress the ERK/AKT signaling pathway. Journal of Molecular Histology. 2025. doi:10.1007/s10735-025-10604-2

BibTeX
@article{Li2025,
  author = {Li, Ying and Mu, Junjie and Chen, Qiuxiong and Ming, Qian and Zhu, Chaohong and Xiao, Yujie and Qiu, Baoli and Zhang, Xue and Zhang, Baoshun and Yang, Xian},
  title = {Study on the mechanism of costunolide inhibiting triple-negative breast cancer by EGFR ubiquitination and degradation to suppress the ERK/AKT signaling pathway},
  journal = {Journal of Molecular Histology},
  year = {2025},
  doi = {10.1007/s10735-025-10604-2}
}
Kostenlos starten →